Morita-Tanaka Satomi, Takayama Koichi
Dept. of Pulmonary Medicine, Kyoto Prefectural University of Medicine.
Gan To Kagaku Ryoho. 2022 Jul;49(7):719-722.
Cancer cachexia(CC)is defined as a multifactorial syndrome that causes anorexia and an ongoing loss of skeletal muscle mass(with or without loss of fat mass). In 2011, the definition of CC was established and in 2021, the novel anti-CC drug, anamorelin was launched in Japan. A new era of CC treatment has begun. However, although anamorelin alone has been shown to increase appetite and lean body mass, it has not been shown to restore skeletal muscle function. Therefore, combined intervention therapy that combines nutrition and exercise interventions is required. Those non-pharmacologic therapy are not yet established, but clinical trials are currently underway in Japan or European countries. Further work on CC is underway to elucidate the mechanisms, establish biomarkers, develop new pharmacotherapies targeting the markers, establish new diagnostic and pathological assessment methods, and establish predictors of the efficacy of anamorelin.
癌症恶病质（CC）被定义为一种多因素综合征，可导致厌食以及骨骼肌质量持续下降（伴有或不伴有脂肪质量下降）。2011年，CC的定义得以确立，2021年，新型抗CC药物阿那莫林在日本上市。CC治疗的新时代已经开启。然而，尽管已证明单独使用阿那莫林可增加食欲和瘦体重，但尚未证明其能恢复骨骼肌功能。因此，需要营养和运动干预相结合的联合干预疗法。这些非药物疗法尚未确立，但目前日本或欧洲国家正在进行临床试验。关于CC的进一步研究正在进行中，以阐明其机制、建立生物标志物、开发针对这些标志物的新药物疗法、建立新的诊断和病理评估方法，以及确定阿那莫林疗效的预测指标。
